News

News from Hemostemix

On October 7, 2026, Hemostemix said it got approval in The Bahamas to run a first-stage study. The approval came from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board) and its Ethics Committee. The study will look at VesCell™, which Hemostemix calls an investigational cell therapy made from a person's own blood. Hemostemix says the study is for angina, vascular dementia and pain. This is a study approval. It is not FDA approval, and it does not show that VesCell works. Our memory screen is not connected to this study and does not qualify anyone for it or for any treatment. Read the full release from Hemostemix (link: https://hemostemix.com/latest-news/hemostemix-announces-full-larta-approval-manufacturing-progress-and-financing-update). Disclosure: VascuMind's owner previously worked with Hemostemix.

MCI Screen Disclaimer

The MCI Screen referenced by VascuMind is a cognitive screening, benchmarking, and tracking tool sourced from MCI Screen / EMBIC materials. It does not diagnose vascular dementia or any other medical condition and is not a substitute for clinical evaluation. Results should be discussed with a qualified healthcare provider.

These products are dietary supplements and are not intended to diagnose, treat, cure, or prevent vascular dementia, Alzheimer’s disease, MCI, stroke, or any other disease. Always consult your healthcare professional before use.

VascuMind® content is for educational purposes only and does not constitute medical advice or clinical guidance. Sudden neurologic symptoms require immediate emergency care (call 911). Supplement pages use structure/function wellness language, affiliate disclosure, and the required FDA dietary-supplement notice. Full compliance page: /compliance.